An Opportunity to Acquire the Intellectual Property of Sirgartan Therapeutics, a Biotech Company (Ref : Sirgartan Holdings Limited - In Liquidation)

Sirgartan Holdings Limited - In Liquidation

An Opportunity to Acquire the Intellectual Property of Sirgartan Therapeutics, a Biotech Company

• Opportunity
• Sirgartan Therapeutics - a Biotech Company has been engaged with developing a new, fast-acting drug (SG001) for obsessive-compulsive disorder (OCD).
• Opportunity to acquire the Company's Interest in research & Intellectual property
• Key Highlights
• A new approach to OCD, the biggest unmet need In psychiatry : SG001 has a completely novel method of action for reducing OCD symptoms
• (SG001) is effective to selectively reduce glutamate neurotransmission in a part of the brain that has shown to be particularly active in human OCD
• Good pre-clinical and early clinical toxicology and efficacy data and ready for phase 2 clinical trial
• UK patent (granted status agreed with the examiner) and filed corresponding IP In the US, Europe and globally
•  * Licensed clinical asset with strong safety and tox pre-clinical data.

For further information, please email Stephen Milner ([email protected])